ArticleAlimentary pharmacology & therapeutics2023

Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.

Adriaan Volkers et al.PubMed ↗Publisher ↗

No numbers read from the abstract.